Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessTarih
2024Yazar
Yiğit Kaya, SüreyyaMutlu, Yaşa Gül
Malkan, Ümit Yavuz
Mehtap, Özgür
Keklik Karadağ, Fatma
Korkmaz, Gülten
Elverdi, Tuğrul
Saydam, Güray
Özet, Gülsüm
Ar, Muhlis Cem
Melek, Elif
Maral, Senem
Kaynar, Leylagül
Sevindik, Ömür Gökmen
Üst veri
Tüm öğe kaydını gösterKünye
Yiğit Kaya, S., Mutlu, Y. G., Malkan, Ü. Y., Mehtap, Ö., Keklik Karadağ, F., Korkmaz, G. ... Sevindik, Ö. G. (2024). Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience. Leukemia Research, 140. http://dx.doi.org/10.1016/j.leukres.2024.107495Özet
Background: Hairy cell leukemia (HCL) is a rare mature B-cell malignancy that is primarily treated with purine analogues. However, relapse remains a significant challenge, prompting the search for alternative therapies. The BRAF V600E mutation prevalent in HCL patients provides a target for treatment with vemurafenib. Patients and methods: This multicenter retrospective study included nine patients with relapsed/refractory (R/R) HCL from six different centers. Patient data included demographics, prior treatments, clinical outcomes, and adverse events. Results: Patients received different treatment regimens between centers, including vemurafenib alone or in combination with rituximab. Despite the differences in protocols, all patients achieved at least a partial response, with seven patients achieving a complete response. Adverse events were generally mild with manageable side effects. The absence of myelotoxic effects and manageable side effects make BRAF inhibitors attractive, especially for patients ineligible for purine analogues or those with severe neutropenia. Conclusion: Single agent vemurafenib or in combination with rituximab appears to be a promising therapeutic option for R/R HCL. Further research is needed to establish standardized treatment protocols and to investigate long-term outcomes.
Scopus Q Kategorisi
Q2Kaynak
Leukemia ResearchCilt
140Koleksiyonlar
- Makale Koleksiyonu [3682]
- PubMed İndeksli Yayınlar Koleksiyonu [4091]
- Scopus İndeksli Yayınlar Koleksiyonu [6366]